WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported higher first-quarter revenue and accelerating demand for its YCANTH treatment as the company advances late-stage clinical trials that could significantly expand the drug’s market reach.
The company reported total first-quarter revenue of $5.0 million for the period ended March 31, including $4.3 million in U.S. net product revenue from YCANTH, up 16.2% from the previous quarter and 25.4% from a year earlier.
Verrica stated that dispensed YCANTH applicator units rose to 15,302 during the quarter, increasing 12.1% sequentially and 51.3% year over year. The company also disclosed that total dispensed units since launch have surpassed 100,000.
YCANTH is currently approved in the United States for treatment of molluscum contagiosum, a viral skin condition that primarily affects children.
The company’s commercial performance comes as Verrica pushes to expand YCANTH into the substantially larger common warts market through a global Phase 3 clinical program.
Verrica announced that enrollment in the first Phase 3 common warts study has surpassed 50% of its current target population. A second Phase 3 trial involving sites in the United States and Japan is expected to begin in mid-2026.
Chief Executive Officer Jayson Rieger said the company believes existing physician relationships and distribution infrastructure supporting YCANTH’s molluscum launch could accelerate adoption in the common warts market if the therapy gains regulatory approval.
The company estimates the U.S. common warts market includes approximately 22 million patients.
Verrica also reported that partner Torii Pharmaceutical has launched YCANTH in Japan following regulatory approval there last year, marking the product’s first commercial expansion outside the United States.
Beyond YCANTH, the company said it continues preparing for a Phase 3 study of VP-315, an investigational treatment for basal cell carcinoma.
Rieger pointed to growing interest in VP-315 following Phase 2 trial results and described Verrica’s late-stage pipeline as a potential driver of future growth if clinical studies and regulatory reviews are successful.
Verrica Pharmaceuticals Inc. shares trade on the Nasdaq under the ticker VRCA.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.